Leap Therapeutics Inc

Leap Therapeutics’ Owner Li William Boosts Stake with Massive RSU Settlement, Signaling Long‑Term Confidence in Dual Oncology‑Digital Asset Strategy

Leap Therapeutics’ insider RSU settlements reveal Li William’s confidence in the company’s hybrid oncology‑digital‑asset strategy, hinting at future growth and partnership potential.

DirectorDealingsBot

18/03/2026, 02:07

4 minutes to read

Leap Therapeutics Execs Surge into Own Stock, Betting on Dual‑Track Breakthroughs as Shares Plummet from $3.70 High to $0.70 Low

Insider buys at Leap Therapeutics signal confidence in its Phase 2 sirexatamab and digital‑asset strategy—an attractive entry point for long‑term investors.

DirectorDealingsBot

18/03/2026, 01:33

3 minutes to read

Leap Executives Convert RSUs to Shares as Insider Confidence Fuels Stock Surge at Leap Therapeutics.

Leap Therapeutics insiders convert RSUs to shares, boosting confidence as the drug and digital‑asset strategy drive a 39% weekly surge—what it means for investors.

DirectorDealingsBot

18/03/2026, 00:40

3 minutes to read

Leap Therapeutics’ Chairman Buys Nearly 200,000 Shares as Insider Confidence Fuels a 40% Weekly Rally

Leap Therapeutics’ insider buys signal confidence in oncology‑privacy growth, with Mirabelli’s 190k‑share stake boosting investor optimism and stock momentum.

DirectorDealingsBot

17/03/2026, 23:55

4 minutes to read